SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Moleculin Biotech Reports Q3 2026 Results and Advances MIRACLE Trial

Moleculin Biotech reported a third-quarter 2026 net loss of $6.5 million, compared with $25.4 million a year earlier, while research and development expenses rose to $4.5 million. The company completed treatment for all 90 patients in Part A of its pivotal MIRACLE trial and expects a comprehensive…

MBRX

Related stories